Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis

Future Science OA

Volumn 4, Issue 4, 2018, Pages

  Soriano, Enrique R ^a   Dellepiane, Analia ^b   Salvatierra, Gabriela ^c   Benítez, Cristian Alejandro ^d   Salinas, Rodrigo Garcia ^e   Baruzzo, Carlos ^f  

^a Instituto Universitario del Hospital Italiano   (Argentina)

^b CEMEC Casilda   (Argentina)

^c Quorum Salud   (Argentina)

^d HOSPITAL GENERAL DE AGUDOS DR COSME ARGERICH   (Argentina)

^e HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^f Sociedad Argentina de Reumatología ^*  (Argentina)

Author keywords

anti TNF agent; certolizumab; rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; DAS28; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; JOINT SWELLING; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; UNSPECIFIED SIDE EFFECT;

EID: 85069006546     PISSN: None     EISSN: 20565623     Source Type: Journal    
DOI: 10.4155/fsoa-2017-0149     Document Type: Article

References (45)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205-2219 (2011)
2. Scott DL, Wolfe F, Huizinga TWJ et al. Rheumatoid arthritis. Lancet 376, 1094-1108 (2010)
3. Sanmarti R, Garcia-Rodriguez S, Alvaro-Gracia JM et al. 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis. Reumatol. Clin. 11, 279-294 (2015)
4. Grupo de estudio de Artritis Reumatoidea. Update of the clinical practice guidelines on rheumatoid arthritis management, Sociedad Argentina de Reumatologia. Buenos Aires, Argentina (2013)
5. Goel N, Stephens S. Certolizumab pegol. MAbs 2, 137-147 (2010)
6. Pasut G. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs 28, 15-23 (2014)
7. Keystone E, Heijde Dv, Mason D Jr et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58, 3319-3329 (2008)
8. Smolen J, Landewe RB, Mease P et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann. Rheum. Dis. 68, 797-804 (2009)
9. Fleischmann R, Vencovsky J, van Vollenhoven RF et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann. Rheum. Dis. 68, 805-811 (2009)
10. Choy E, McKenna F, Vencovsky J et al. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology 51, 1226-1234 (2012)
11. Smolen JS, van Vollenhoven R, Kavanaugh A et al. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis Res. Ther. 17, 245 (2015)
12. Yamamoto K, Takeuchi T, Yamanaka H et al. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. Mod. Rheumatol. 24, 552-560 (2014)
13. Atsumi T, Yamamoto K, Takeuchi T et al. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann. Rheum. Dis. 75, 75-83 (2016)
14. Emery P, BinghamCO, Burmester GR et al. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-näive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann. Rheum. Dis. 76, 96-104 (2017)
15. Schiff MH, von Kempis J, Goldblum R, Tesser JR, Mueller RB. Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a Phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Ann. Rheum. Dis. 73, 2174-2177 (2014)
16. Weinblatt ME, Fleischmann R, van Vollenhoven RF et al. Twenty-eight-week results from the REALISTIC Phase IIIB randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Res. Ther. 17, 325 (2015)
17. Tanaka Y, Yamamoto K, Takeuchi T et al. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. Mod. Rheumatol. 24, 734-743 (2014)
18. Keystone E, Landewe R, van Vollenhoven R, Combe B, Strand V, Mease P et al. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Ann. Rheum. Dis. 73, 2094-2100 (2014)
19. Fleischmann R, van Vollenhoven RF, Vencovsky J et al. Long-term maintenance of certolizumab pegol safety and efficacy, in combination with methotrexate and as monotherapy, in rheumatoid arthritis patients. Rheumatol. Ther. 4, 57-69 (2017)
20. Cimzia. Summary of product characteristics. www.ema.europa.eu/docs/en GB/document library/EPAR - Product Information/human/001037/WC500069763.pdf
21. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315-324 (1988)
22. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38, 44-48 (1995)
23. Fransen J, van Riel PLCM. The Disease Activity Score and the EULAR response criteria. Rheum. Dis. Clin. North Am. 35, 745-757 (2009)
24. Smolen JS, Breedveld FC, Schiff MH et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42, 244-257 (2003)
25. Gliklich R, Dreyer N, Leavy M. Registries for Evaluating Patient Outcomes: A User's Guide (3rd Edition). Agency for Healthcare Research and Quality, MD, USA (2014)
26. Chatzidionysiou K, Kristensen L-E, Eriksson J, Askling J, van Vollenhoven R, ARTIS Group. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register. Scand. J. Rheumatol. 44, 431-437 (2015)
27. Iannone F, Carlino G, Marchesoni A et al. Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA. Joint Bone Spine 83, 721-725 (2016)
28. Torrente-Segarra V, Urruticoechea Arana A, Sanchez-Andrade Fernandez A et al. RENACER study: assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database. Mod. Rheumatol. 26, 336-341 (2016)
29. Rein P, Mueller RB. Treatment with biologicals in rheumatoid arthritis: an overview. Rheumatol. Ther. 4, 247-261 (2017)
30. Smolen JS, Burmester G-R, Combe B et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet 388, 2763-2774 (2016)
31. Hyrich KL, Watson KD, Silman AJ, Symmons DPM. British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 45, 1558-1565 (2006)
32. van der Heijde D, Klareskog L, Landewe R et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 56, 3928-3939 (2007)
33. Tanaka Y, Takeuchi T, Inoue E et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Mod. Rheumatol. 18, 146-152 (2008)
34. Iwamoto N, Kawakami A, Fujikawa K et al. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. Mod. Rheumatol. 19, 488-492 (2009)
35. Makinen H, Kautiainen H, Hannonen P et al. Disease activity score 28 as an instrument to measure disease activity in patients with early rheumatoid arthritis. J. Rheumatol. 34, 1987-1991 (2007)
36. Belmonte Serrano M. Is the DAS28 Score the most adequate method to estimate activity in rheumatoid arthritis? Clinimetric considerations and simulations scenarios. Reumatol. Clin. 4, 183-190 (2008)
37. Ton E, Bakker M, Verstappen S et al. Look beyond the Disease Activity Score of 28 joints (DAS28): tender points influence the DAS28 in patients with rheumatoid arthritis. J. Rheumatol. 39, 22-27 (2012)
38. Van der Heijde D, Keystone EC, Curtis JR et al. Timing and magnitude of initial change in Disease Activity Score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. J. Rheumatol. 39, 1326-1333 (2012)
39. Berenbaum F, Pham T, Claudepierre P et al. Early non-response to certolizumab pegol in rheumatoid arthritis predicts treatment failure at one year. Data from a randomised Phase III clinical trial. Joint Bone Spine 85(1), 59-64 (2017)
40. Keystone EC, Curtis JR, Fleischmann RM et al. Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better long-term outcomes: post-hoc analysis of a randomized controlled trial. J. Rheumatol. 38, 990-996 (2011)
41. Takeuchi T, Yamamoto K, Yamanaka H et al. Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies. Mod. Rheumatol. 25, 11-20 (2015)
42. Cheung TT, McInnes IB. Future therapeutic targets in rheumatoid arthritis? Semin. Immunopathol. 39, 487-500 (2017)
43. Mankia K, Emery P. A new window of opportunity in rheumatoid arthritis: targeting at-risk individuals. Curr. Opin. Rheumatol. 28, 260-266 (2016)
44. Manivel VA, Mullazehi M, Padyukov L et al. Anticollagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during 5 years follow-up. Ann. Rheum. Dis. 76, 1529-1536 (2017)
45. Sparks JA, Iversen MD, Yu Z et al. Disclosure of personalized rheumatoid arthritis risk using genetics, biomarkers, and lifestyle factors to motivate health behavior improvements: a randomized controlled trial. Arthritis Care Res. (Hoboken) doi:10.1002/acr.23411 (2017) (Epub ahead of print).